12:00 AM
Jul 15, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Boniva Ibandronate regulatory update

Chugai and Taisho said Japan's Ministry of Health, Labor and Welfare (MHLW) approved an NDA for monthly IV Bonviva ibandronate to treat osteoporosis. Chugai partnered with Taisho in 2006 to co-develop and co-market the bisphosphonate that inhibits...

Read the full 171 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >